Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

[1]  S. Hall,et al.  The interaction of diltiazem with lovastatin and pravastatin , 1998, Clinical pharmacology and therapeutics.

[2]  P. Neuvonen,et al.  Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. , 1998, British journal of clinical pharmacology.

[3]  P. Neuvonen,et al.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.

[4]  B H Arison,et al.  In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[5]  P. Neuvonen,et al.  Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole , 1997, Clinical pharmacology and therapeutics.

[6]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[7]  M. Horn.  Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. , 1996, Archives of dermatology.

[8]  I. Vandewiele,et al.  Drug-interaction-induced rhabdomyolysis. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  P. Neuvonen,et al.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.

[10]  P. Neuvonen,et al.  Diltiazem enhances the effects of triazolam by inhibiting its metabolism , 1996, Clinical pharmacology and therapeutics.

[11]  T. Leemann,et al.  In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)‐fluvastatin , 1995, Clinical pharmacology and therapeutics.

[12]  R. Lees,et al.  Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. , 1995, The New England journal of medicine.

[13]  P. Neuvonen,et al.  Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. , 1995, Clinical pharmacology and therapeutics.

[14]  P. Neuvonen,et al.  Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole , 1994, Clinical pharmacology and therapeutics.

[15]  P. Neuvonen,et al.  Dose of midazolam should be reduced during diltiazem and verapamil treatments. , 1994, British journal of clinical pharmacology.

[16]  A. Hiller,et al.  A potentially hazardous interaction between erythromycin and midazolam. , 1993, Clinical pharmacology and therapeutics.

[17]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[18]  B. Arison,et al.  In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[19]  G. Vantrappen,et al.  Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. , 1990, The New England journal of medicine.

[20]  I. Chen,et al.  Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[21]  I. Chen,et al.  The physiological disposition of lovastatin. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[22]  H. Jaeger,et al.  Quantitative determination of verapamil and metabolites in human serum by high-performance liquid chromatography and its application to biopharmaceutic investigations. , 1989, Arzneimittel-Forschung.

[23]  U. Bondesson,et al.  Liquid-chromatographic quantification compared with gas-chromatographic-mass-spectrometric determination of verapamil and norverapamil in plasma. , 1988, Clinical chemistry.

[24]  J. Horn,et al.  Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy , 1986, Clinical pharmacology and therapeutics.

[25]  Worldwide labelled warning for mibefradil , 1997 .

[26]  M. Scheinin,et al.  Determination of erythromycin base and 2'-acetylerythromycin in human plasma using high-performance liquid chromatography with electrochemical detection. , 1990, Journal of chromatography.

[27]  R. Stubbs,et al.  Determination of mevinolin and mevinolinic acid in plasma and bile by reversed-phase high-performance liquid chromatography. , 1986, Journal of chromatography.